Shares of several biotech firms fell in premarket trading Monday after reports that ousted U.S. Food and Drug Administration ...

Vinay Prasad, a top vaccine regulator ousted from the Food and Drug Administration (FDA) late last month, is set to return to ...

Novavax on Wednesday raised its full-year revenue forecast as it received a $175 million milestone payment from Sanofi ...

Novavax tops Q2 estimates and lifts 2025 sales forecast as Sanofi takes over global rollout of its COVID vaccine.

Less than weeks after stepping down, Prasad will return to lead CBER “at the FDA’s request,” according to an HHS spokesperson ...

The FDA's Dr. Vinay Prasad said that he disagreed with the agency's career vaccine reviewers about COVID shot approvals.

Vinay Prasad, who came under fire from patient advocacy groups and Laura Loomer, is gone after less than three months on the ...

The government’s top vaccine official working under Health Secretary Robert F. Kennedy Jr. recently restricted the approval of two COVID-19 vaccines, disregarding recommendations from government ...

In Danes over age 65, the vaccine effectiveness of the JN.1-based mRNA boosters reached 70-85% against COVID-related ...

The Food and Drug Administration (FDA) signed off Wednesday on an emergency use authorization for the Novavax COVID-19 vaccine for individuals 18 years of age and older.

In a memorandum following Novavax's approval in May, which narrowed the shot's label to only seniors ages 65 and older and others at-risk of severe disease, the FDA's Dr. Vinay Prasad said that he ...

Novavax’s vaccine is the only protein-based coronavirus vaccine available in the U.S. Moderna’s vaccine is an updated, lower-dose version of its existing mRNA-based vaccine.